| Literature DB >> 34438146 |
María Fernanda Montenegro-Landívar1, Paulina Tapia-Quirós1, Xanel Vecino2, Mònica Reig1, César Valderrama1, Mercè Granados3, José Luis Cortina4, Javier Saurina3.
Abstract
Fruits, vegetables, spices, and herbs are a potential source of phenolic acids and polyphenols. These compounds are known as natural by-products or secondary metabolites of plants, which are present in the daily diet and provide important benefits to the human body such as antioxidant, anti-inflammatory, anticancer, anti-allergic, antihypertensive and antiviral properties, among others. Plentiful evidence has been provided on the great potential of polyphenols against different viruses that cause widespread health problems. As a result, this review focuses on the potential antiviral properties of some polyphenols and their action mechanism against various types of viruses such as coronaviruses, influenza, herpes simplex, dengue fever, and rotavirus, among others. Also, it is important to highlight the relationship between antiviral and antioxidant activities that can contribute to the protection of cells and tissues of the human body. The wide variety of action mechanisms of antiviral agents, such as polyphenols, against viral infections could be applied as a treatment or prevention strategy; but at the same time, antiviral polyphenols could be used to produce natural antiviral drugs. A recent example of an antiviral polyphenol application deals with the use of hesperidin extracted from Citrus sinensis. The action mechanism of hesperidin relies on its binding to the key entry or spike protein of SARS-CoV-2. Finally, the extraction, purification and recovery of polyphenols with potential antiviral activity, which are essential for virus replication and infection without side-effects, have been critically reviewed.Entities:
Keywords: Agri-food residues; Antioxidant properties; Antiviral activity; Phenolic compounds; Polyphenol recovery; Viral diseases
Mesh:
Substances:
Year: 2021 PMID: 34438146 PMCID: PMC8373592 DOI: 10.1016/j.scitotenv.2021.149719
Source DB: PubMed Journal: Sci Total Environ ISSN: 0048-9697 Impact factor: 7.963
Different families and type of viruses, their specific virus and the role of polyphenols as a possible alternative to treat virus.
| Type of virus | Specific virus | Disease characteristics | Conventional treatment | Alternative treatment with polyphenols | Reference |
|---|---|---|---|---|---|
| Respiratory infections | Influenza virus (A, B and C) | Annually responsible for high mortality in both humans and animals worldwide | NA inhibitors and M2 protein channel blockers after infection, while vaccination is the most effective therapy | 1,2,3,4,6-Penta-O-galloyl-ß- | ( |
| Coronavirus (HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and the novel SARS-CoV-2) | Respiratory tract infections in humans with outbreaks around the world, especially in winter | Currently there are no specific treatments for the CoV infection and preventive vaccines are being developed | Polyphenol extract from | ( | |
| Rhinovirus | The main cause of the common cold, among other respiratory diseases, also producing shortness of breath in asthmatic people, acute otitis and bronchiolitis | There are no vaccines or antiviral agents for the prevention or treatment of this virus | Resveratrol showed a therapeutic approach to reduce infection when the IC50 was 50 μM | ( | |
| Syncytial virus | Causes infections in infants and the elderly, causing not only acute morbidity but also recurrent breathing problems | There is no safe and effective treatment. | Resveratrol (IC50 189 pg/mL) inhibits 40% virus replication and down-regulates the TIR-domain-containing adapter-inducing interferon-β (TRIF) complex, which sends signals for the activation of innate immune cells | ( | |
| Gastrointestinal infections | Rotavirus | Causes dehydrating gastroenteritis, especially in children under five years of age | There is a vaccine against rotavirus but annually the mortality is around 200,000 deaths worldwide. The treatment focuses on dehydration and not on the use of antiviral agents | Polyphenols (licocoumarone, glycyrin, among others) extracted from | ( |
| Hepatic infections | Hepatitis virus (A, B and C) | Cause high morbidity and mortality around the world | Anti-hepatitis virus drugs are members of nucleotides or nucleoside analogs, which inhibit the activity of polymerase or reverse transcriptase, but the prolonged use giving rise to the existence of mutant viruses | Curcumin (150 μM) inhibits hepatitis B virus | ( |
| Epstein–Barr virus | Infects human epithelial and lymphoid cells. Infection is associated with a number of human cancers, such as Hodgkin's disease | A vaccine is not yet approved | (−)-Epigallocatechin gallate (EGCG) extracted from green tea (50 μM) blocked the EBV lytic cycle, inhibiting the transcription of immediate-early genes in a range of 40–50% | ( | |
| Human cytomegalovirus | Not present obvious symptoms, but infection causes morbidity and mortality in transplant recipients or patients with acquired immunodeficiency syndrome (AIDS) | Drugs such as cidofovir, valganciclovir and ganciclovir, which target viral DNA polymerase, but their side-effects include long-term toxicity, low bioavailability, plus drug resistance to the virus | Curcumin, using a low dose of 0.2 μg/mL, inhibits virus protein expression | ( | |
| Herpes simplex virus (HSV-1 and HSV-2) | Responsible for orolabial and genital diseases producing, in general, benign lesions but, in some cases, putting the life of patients at risk if the infections are recurrent | There is no vaccine and existing drugs (e.g., acyclovir) do not eradicate the virus infection and cause resistance to drugs | Ent-epiafzelechin-(4 ∝ → 8)-epiafzelechin extracted from | ( | |
| Exanthematous infections | Varicella-zoster virus | Causes fever and vesicular rash. Once the disease has disappeared, the virus enters into a state of latency, but it can be reactivated due to stress, causing herpes zoster and acute pain in latently infected lymph nodes | Generally, uses drugs such as acyclovir, valaciclovir, etc., which are often combined with analgesics for pain and corticosteroids for inflammation | Resveratrol (219 μM of) inhibits 100% virus replication | ( |
| Neurologic infections | Rabies virus | Causes an acute and fatal neurological infection in humans and mammals | Disease can be prevented by vaccination | Tannin pentagalloylglucose (PGG) (10 μM) for 24 h possess significant anti-RABV activity; PGG can reverse the expression of miR-455-5p (a microRNA whose excess production regulates host cell signalling pathways and innate immune responses) | ( |
| Polio virus | The virus drains into the cervical and mesenteric lymph nodes and then into the blood, causing a transient viremia | The incidence has been largely reduced especially by the use of a vaccine, but the disease is still endemic in Africa and Asia | Extract of | ( | |
| Haemorrhagic fevers | Dengue virus | Causing from a mild fever to haemorrhagic fever, nausea, joint pains, etc. | There are no effective vaccines, and the prevention options available for the control of the virus infection are very limited | Baicalein (IC50 was 7.14 μg/mL) potent antiviral agent against adsorption in the host and after entry viral replication, and IC50 of 1.55 μg/mL presents a virucidal effect | ( |
| Sindbis virus | Cause of disease outbreaks in humans in South Africa and Northern Europe | There are no vaccines or therapeutic means | Hesperidin and naringenin with a 50% inhibitory dose (ID50) of 20.5 μg/mL and 14.9 μg/mL respectively, reaching 50% for hesperidin and up to 80% for naringenin of virus replication inhibition | ( | |
| Immune system infection | Human immunodeficiency virus (HIV-1 and HIV-2) | Spreads through certain body fluids and attacks the immune system, destroying T lymphocytes. Thus, the body loses its ability to fight infections and diseases | Since HIV was discovered, there has been no preventive vaccine for virus infection, and the applied treatment is antiretroviral therapy drugs which help control the multiplication of HIV in infected patients | Tricyclic coumarin compound from | ( |
| Multisystem diseases | Coxsackie virus | Causes muscle injury, paralysis and death | There is no specific treatment or vaccine available | Apigenin ((EC50 of 9.7 mg/L) and ursolic acid (EC50 of6.6 mg/L) extracted from | ( |
List of relevant polyphenol classified according to their structure (adapted from Saurina and Sentellas, 2015).
| Class | Structure | Substitutions | Examples |
|---|---|---|---|
| Phenolic acids | R1: H, OH, OCH3 | Gallic acid | |
| R1: H, OH, OCH3 | Caffeic acid | ||
| Flavonoids | R1: H, OH | Hesperidin | |
| R1: H, OH | Cyanidin | ||
| R1-R3: OH | Catechin | ||
| R1: OH | Genistein | ||
| R1-R5: H, OH | Xanthohumol | ||
| Lignans | R1-R2: H, OH | Enterodiol | |
| Stilbenes | R1-R4: H, OH, OCH3 | Resveratrol |
Summary of relevant polyphenols present in plants with antiviral activity according to the reviewed publications.
| Plant source | Polyphenol | Type of virus | Reference |
|---|---|---|---|
| Berries, tea, almond, beans, tomato, | Kaempferol | Coronavirus, rotavirus, human cytomegalovirus, HSV-1 and HSV-2, coxsackie B virus | ( |
| Propolis, | Chrysin | Coronavirus, rotavirus, human cytomegalovirus, HSV-1 and HSV-2, coxsackie B virus | ( |
| Catechin | HIV, HSV-1 | ( | |
| Quercetin | Rabies virus, poliovirus, syncytial virus, HSV-2, respiratory syncytial virus, dengue virus, coronavirus | ( | |
| Quercitrin | Rabies virus, HSV-1, influenza virus | ( | |
| Rutin | Rabies virus, influenza virus, dengue virus | ( | |
| Hesperidin | Influenza virus, HSV, poliovirus, syncytial virus, SARS-CoV-2 | ( | |
| Chamomile, parsley, oregano, thyme, grapefruit, orange, onion, mango | Apigenin | HSV-1, HIV | ( |
| Naringin | Respiratory syncytial virus | ( | |
| Broadleaf plantain ( | Caffeic acid | HIV, HSV | ( |
| Broccoli, rosemary, pistachio, lentils, olive, artichoke, lemon, | Luteolin | HSV-1 and HSV-2 | ( |
| Berries, pomegranate, walnuts, pecans | Ellagic acid | Dengue virus, hepatitis A and B | ( |
| Grape, berries, peanuts | Resveratrol | Influenza A, hepatitis C virus, respiratory syncytial virus, varicella-zoster virus, Epstein–Barr virus, HSV, HIV | ( |
Applications of extracted polyphenols from different plant sources to treat several target viruses.
| Antiviral polyphenol | Plant source | Target virus | Extraction technique | Purification technique | Study effectiveness against virus | Results | Scaling-up | Reference |
|---|---|---|---|---|---|---|---|---|
| 1,2,3,4,6-Penta-O-galloyl-ß- | Pomegranate | Influenza A (H1N1) | Maceration | Sephadex LH-20 column | EC50 2.36 ± 0.29 μg/mL of PGG 5 or 8 h upon infection | Significant inhibition virus release | Lab scale | ( |
| Extract rich in polyphenols | Influenza A (H1N1) | PLE | – | In vivo oral administration (10 and 20 mg/kg) for 5 days | Infected mice reduce the production of nitric oxide, pro-inflammatory cytokines, TNF-α and IL-6 | Pilot scale | ( | |
| Isoquercetin (quercetin glucoside form) | Influenza A (H1N1) | Maceration | – | In vivo administrated intraperitoneal | Reduce virus titres and pathological changes in lungs of mice infected with influenza A (H1N1) by up to 20-fold at 1:500 ( | Pilot scale | ( | |
| Baicalein | Influenza H1N1 | Maceration | – | In vivo oral administration | Infected mice showed significant therapeutic activities, including death prevention and lung virus titre reduction | Pilot scale | ( | |
| Quercetin, kaempferol, myricetin, quercetin-3- | Influenza (H3N2) | Maceration | – | Administered in aerosol way (dose 5.4 mg/mL) | Around 70% was the protective index and the survival time was in a range of 2.9–4.9 days, the animal lung infectious virus titre was reduced in comparison with control | Pilot scale | ( | |
| Epigallocatechingallate (EGCG), epigallocatechin (EGC), epicatechingallate (ECG), epicatechin (EC) and catechin gallate | Tea | Influenza | Maceration | – | 76 adult persons around 65 years old gargling 200 mg/mL 3 times daily for 3 months | The catechin-treated group have lower incidence of influenza infection than the control group | Pilot scale | ( |
Selected polyphenols and their role against SARS-CoV-2.
| Polyphenol | Source | Mechanism of action | Analysis study | Reference |
|---|---|---|---|---|
| Kaempferol, quercetin, luteolin-7-glucoside, demethoxycurcumin, naringenin, apigenin-7-glucoside, oleuropein, curcumin, catechin, epicatechingallate, zingerol, gingerol, and allicin | Medicinal plants | Block the enzymatic activity of SARS-CoV-3CLpro | In silico | ( |
| Malvidin, peonidin, petunidin, pelargonidin, cyanidin and malvidin | Binding affinities to 3C-like protease of SARS-CoV-2 (virus replication) | In silico | ( | |
| Hesperetin, myricetin, caflanone, linebacker | Medicinal plants | High affinity to protein S, helicase and protease sites on the CE2 receptor (in silico analysis); in vitro analysis shows potential caflanone to inhibit virus entry | In silico and in vitro | ( |
| Baicalein and baicalin | Down-regulators of the TMPRSS-2 expression. Baicalein (IC50 of 0.94 μM) and baicalin (6.41 μM) promising results to 3Clpro | In silico and in vitro | ( | |
| Polyphenol extract | Virus inactivated upon treatment with 50 μg/mL | In vitro | ( |
Fig. 1Virus replication and polyphenol targets (adapted from Pommier et al., 2005; Kamboj et al., 2012).
Examples of antiviral mechanism of polyphenols (adapted from Naithani et al., 2008; Haslberger et al., 2020).
| Antiviral polyphenol | Plant source | Study | Virus type | Main mechanism |
|---|---|---|---|---|
| 4′,5-Dihydroxy 3,3′,7-trimethoxy flavone | Effect on the replication virus | Rhinovirus coxsackie virus | Replication inhibition, selective inhibition of viral RNA synthesis in the cell culture | |
| Quercetin Luteolin | Effect on the viral replication cycle of HSV-1 | HSV-1 | Interferes with the events occurring between the third and ninth hour of HSV-1 replication cycle, which includes transcription and translation of viral proteins | |
| Salvin | Viral inhibitory before absorption stage | HSV-1, HIV, SARS-CoV | Efficacy before absorption stage, but not in the replication stage | |
| Morin | Effect on viral replication | HIV | Blockage of RNA synthesis, exhibited HIV-inhibitory activity |